• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Executive Moves: Daiichi Sankyo Co.

    Valitacell, Solentim Form Biologics Collaboration

    Werum, B-EN-G Enter Partnership

    Janssen, Morphic Ink Deal Worth up to $750M

    Catalent Appoints Tech Ops SVP
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Oakrum, Aucta Form Devt. & Mfg. Partnership

    Emergex Secures State-of-the-Art R&D Facility

    WuXi Biologics Completes EMA GMP Inspection

    Achillion Expands with Launch of PA Office

    ACG Capsules Expands in Brazil
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    ACG Capsules Expands in Brazil

    Catalent Receives P&G Award

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Implementing AI in Drug Discovery

    Valitacell, Solentim Form Biologics Collaboration

    Werum, B-EN-G Enter Partnership

    Janssen, Morphic Ink Deal Worth up to $750M

    Merck to Acquire Immune Design for $300M
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    WuXi Biologics Completes EMA GMP Inspection

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Federal Equipment Company

    Emergent BioSolutions, Inc.

    Ascendia Pharmaceuticals

    Aphena Pharma Solutions, Inc.

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Ajinomoto Bio-Pharma Services

    Reed-Lane, Inc.

    Jubilant HollisterStier Contract Manufacturing & Services

    Aphena Pharma Solutions, Inc.

    Vetter Pharma International GmbH
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    10 Lilly

    Related CONTENT
    • Five Prime Achieves $25M BMS Milestone
    • BMS Inks Massive $3.6B Deal for Nektar Cancer Drug
    • Clarke Solutions to Address Serialization and Packaging Challenges
    • Peter Stein to Deliver FDA Keynote Presentation
    • BMS and Flatiron Health Expand Collaboration
    07.20.18
    Headquarters: Indianapolis, IN
    twitter.com/EliLillyCo
    www.lilly.com

    Headcount: 38,131
    Year Established: 1876
    Revenues:  $22,871  (+8%)
    LOSS:   $204  (n/a)
    R&D:  $5,282  (+1%)

    TOP SELLING DRUGS  
    Drug Indication 2017 Sales (+/-%)
    Humalog diabetes $2,865 3%
    Cialis erectile dysfunction $2,323 -6%
    Alimta cancer $2,062 -10%
    Trulicity type 2 diabetes $2,029 119%
    Forteo osteoporosis $1,749 17%
    Humulin diabetes $1,335 -2%
    Cyramza solid tumors $758 23%
    Cymbalta anxiety, depression $757 -19%
    Erbitux head and neck cancer $646 -6%
    Strattera ADHD $618 -28%

    In 2017 Eli Lilly and Co. reported an 8% growth in revenue to $23 billion from $21 billion the year before. Sales in Endocrinology increased 25 percent primarily driven by growth of Trulicity, Basaglar, Forteo, Jardiance, and Trajenta. Oncology grew 2 percent primarily due to higher volumes for Lartruvo and Cyramza, partially offset by lower volumes for Alimta, and Immunology grew due to higher volumes for Taltz. Revenue in Neuroscience decreased 20 percent driven by lower volumes for Strattera, Cymbalta, and Zyprexa due to loss of patent protection, and Cardiovascular decreased 11 percent driven by lower volumes for Cialis and Effient.

    In new products approvals, at the end of September 2017 the FDA approved Lilly’s Verzenio (abemaciclib) to treat breast cancer. Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy. Breast cancer is the most common form of cancer in the U.S. and Verzenio has the potential to be an important treatment option for patients.

    Expanding the pipeline through acquisition
    In 2017 Lilly acquired CoLucid for approximately $960 million, enhancing its portfolio in pain management for migraine with a potential near-term launch. CoLucid is developing an oral 5-HT1F agonist (lasmiditan) for the acute treatment of migraine and has completed the first of two Phase III trials, and pending results, submission of lasmiditan for U.S. regulatory approval are scheduled for 2018.

    If approved, Lasmiditan would be a first-in-class therapy to treat migraine through a novel mechanism of action without vasoconstriction. This could be desirable in migraine patients who have, or are at risk for, cardiovascular disease, as well as those who are dissatisfied with their current therapies.

    Lasmiditan was originally discovered at Lilly and was out-licensed to CoLucid in 2005. CoLucid has taken important steps to decrease the risk related to development and commercialization of lasmiditan. Lilly has since reorganized its R&D efforts to focus on migraine as part of its emerging therapeutic area of pain.

    In more recent acquisition news, Lilly entered an agreement in May 2018 to acquire ARMO BioSciences for approximately $1.6 billion, expanding its portfolio of immuno-oncology therapies. ARMO, based in Redwood City, CA is developing cancer treatments that harness the body’s immune system to fight tumors. Its lead candidate, AM0010 is being investigated in a pivotal Phase III trial in pancreatic cancer. According to Armo, AM0010 has demonstrated clinical benefit on its own, but can also be combined with chemotherapy and checkpoint inhibitor therapies across several tumor types.

    AM0010, a long-acting form of recombinant human interleukin 10 (IL-10) linked to polyethylene glycol (PEG), is also being investigated in Phase II studies in combination with Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo in patients with metastatic non-small-cell lung cancer.

    Armo’s immune-oncology pipeline also includes several preclinical candidates—AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12).

    Development deals and supply pacts
    Lilly and Purdue University entered a strategic five-year agreement, under which Lilly will provide as much as $52 million to develop improved delivery of injectable medicines to reduce pain, number of injections, and improve patient compliance. The collaboration will also focus on developing predictive models for clinical trials that reduce risks associated with investing in drug development and more effectively predict the outcome of new therapies in humans. The collaboration aims to expand to other areas to further leverage the range of expertise at the two institutions.

    Also, Rimidi and Lilly are partnering to develop provider-focused tools that will integrate personalized solutions for people who use insulin to manage their diabetes. Under the partnership, Rimidi will integrate its diabetes management software platform with Lilly’s integrated insulin management system in development.

    The non-exclusive agreement aims to make diabetes management easier for the approximately 30 million Americans by helping people use insulin more effectively while optimizing diabetes management within the normal clinical workflow.

    Rimidi’s platform helps clinicians personalize care by leveraging the individual characteristics and clinical histories of people with diabetes to identify individuals who may benefit from specific management approaches. Lilly’s insulin management system combines a connected insulin pen with glucose-sensing technologies (e.g., glucose meter, CGM) and software applications to deliver personalized insulin dose recommendations. Data from these devices and apps will flow back to physicians.

    With Evonik Industries, Lilly renewed a long-term supply agreement for active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly human and veterinary drug products. Evonik acquired Lilly’s Tippecanoe site in Lafayette, IN, in January 2010. Since then, the facility has been operating as a contract development and manufacturing organization (CDMO) for the pharma industry, serving more than 20 Evonik customers. The facility has 170 cubic meters of high potency APIs (HPAPIs) capacity and a total of 860 cubic meters of cGMP manufacturing. 
    Related Searches
    • apis
    • bristol-myers squibb
    • cGMP
    • Clinical Trials
    Suggested For You
    05	Merck 05 Merck
    04	Johnson & Johnson 04 Johnson & Johnson
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    12	AstraZeneca 12 AstraZeneca
    11	Amgen 11 Amgen
    Corbus Announces Key Hires Corbus Announces Key Hires
    Lilly to Acquire Armo BioSciences for $1.6B Lilly to Acquire Armo BioSciences for $1.6B
    Financial Report: Lilly Financial Report: Lilly
    Financial Report: Bristol-Myers Squibb Financial Report: Bristol-Myers Squibb
    Motif Bio Appoints Clinical Development VP Motif Bio Appoints Clinical Development VP
    BMS and Flatiron Health Expand Collaboration BMS and Flatiron Health Expand Collaboration
    Peter Stein to Deliver FDA Keynote Presentation Peter Stein to Deliver FDA Keynote Presentation
    Clarke Solutions to Address Serialization and Packaging Challenges Clarke Solutions to Address Serialization and Packaging Challenges
    BMS Inks Massive $3.6B Deal for Nektar Cancer Drug BMS Inks Massive $3.6B Deal for Nektar Cancer Drug
    Five Prime Achieves $25M BMS Milestone Five Prime Achieves $25M BMS Milestone

    Related Top Companies Report

    • 08	AbbVie

      08 AbbVie

      Headquarters: North Chicago, IL twitter.com/abbvie www.abbvie.com Headcount:  29,000 Year Established: 2013 Revenues:  $28,216  (+10%) Net Income:  $5,309  (-11%) R&D:  $4,982  (+14%) TOP SELLING DRU…
      07.20.18

    • 07	GlaxoSmithKline

      07 GlaxoSmithKline

      Headquarters: Brentford, Middlesex, UK twitter.com/GSK www.gsk.com Headcount: 99,300  Year Established: 2000 Revenues:  $40,725 (+7%) Pharma Revenues:  $30,270 (+8%) Net Income:  $5,514  (+57%) R&D:  $6,039…
      07.20.18

    • 06	NOVARTIS

      06 NOVARTIS

      Headquarters: Basel, Switzerland twitter.com/novartis www.novartis.com Headcount: 124,000 Year Established: 1996 Revenues:  $49,109  (+1%) Pharma Revenues:  $33,025  (-1%) Net Income:  $7,703  (+15%) R&D:&n…
      07.20.18


    • 05	Merck

      05 Merck

      Headquarters: Whitehouse Station, NJ twitter.com/Merck www.merck.com Headcount:  69,000 Year Established:  1889 Revenues: $40,122  (+1%) Pharma Revenues:  $35,390  (+1%) Net Income:  $2,592  (-34%) R&D…
      07.20.18

    • 04	Johnson & Johnson

      04 Johnson & Johnson

      Headquarters: New Brunswick, NJ twitter.com/JNJComm www.jnj.com Headcount: 134,000 Year Established: 1887 Revenues:  $76,450  (+6%) Pharma Revenues:  $36,256  (+7%) Net Income:  $1,300  (-92%) R&D:  $1…
      07.20.18

    • 03	Sanofi

      03 Sanofi

      Headquarters: Paris, France twitter.com/sanofi www.sanofi.com Headcount: 106,566 Year Established: 2004 Revenues:  $41,991  (+4%) Net Income: $11,192  (+1%) R&D: $6,555  (+6%) TOP SELLING DRUGS  …
      07.20.18


    • 02	Roche

      02 Roche

      Headquarters: Basel, Switzerland twitter.com/Roche www.roche.com Headcount: 93,734  Year Established: 1896 Total Revenues: $54,591  (+5%) Pharma Revenues: $42,219  (+5%) Net Income: $9,039  (-9%) R&D: $11,566  (…
      07.20.18

    • 25	Otsuka

      25 Otsuka

      Headquarters: Tokyo, Japan www.otsuka.com Headcount: 31,800 Year Established: 1921 Revenues:    $11,006  (+4%) Net Income:  $1,015   (+23%) R&D:         $1,558&nbs…
      07.20.18

    • 24	Mylan

      24 Mylan

      Headquarters: Canonsburg, PA twitter.com/MylanNews www.mylan.com Headcount:  35,000 Year Established: 1970 Revenues:   $11,908    (+8%) Net Income:      $696  (+45%) R&D: &…
      07.20.18


    • 23	ASTELLAS

      23 ASTELLAS

      Headquarters: Tokyo, Japan twitter.com/AstellasUS www.astellas.com Headcount:    16,617 Year Established: 2005 Revenues:       $12,238 (-1%) Net Income:  $1,836  (-4%) R&D: &nbs…
      07.20.18

    • 22	Biogen

      22 Biogen

      Headquarters: Cambridge, MA twitter.com/biogenidec www.biogenidec.com Headcount: 7,300 Year Established: 2003 Revenues:  $12,274  (+7%) Net Income:   $2,539  (-31%) R&D:  $2,254  (+14%) Top Selling D…
      07.20.18

    • 21	Celgene

      21 Celgene

      Headquarters: Summit, NJ twitter.com/celgene www.celgene.com Headcount: 7,000 Year Established: 1986 Revenues:   $13,003  (+16%) Net Income:  $2,940  (+47%) R&D:  $5,915 (+32%) TOP SELLING DRUGS …
      07.20.18

    • Analytical Services | APIs | Capsules
      01	Pfizer, Inc.

      01 Pfizer, Inc.

      Headquarters: New York, NY twitter.com@pfizer_news www.pfizer.com Headcount: 90,000 Year Established: 1849 Revenues: $52,546  (-1%)  Net Income: $21,308  (+195%) R&D: $7,657  (-3%) TOP SELLING DRUGS…
      07.20.18

    • 20	SHIRE

      20 SHIRE

      Headquarters: Lexington, MA twitter.com/shireplc www.shire.com Headcount:  22,000 Year Established: 1986 Revenues:  $14,449  (+33%) Net Income:  $4,272  (n/a) R&D:  $1,763  (+23%) Top Selling Drugs&n…
      07.20.18

    • 19	Boehringer-Ingelheim

      19 Boehringer-Ingelheim

      Headquarters: Ingelheim, Germany twitter.com/Boehringer www.boehringer-ingelheim.com Headcount:  50,000 Year Established: 1817 Pharma Revenues:      $15,930   (+5%) LOSS:  $235  (-112%) R&…
      07.20.18

    Breaking News
    • Valitacell, Solentim Form Biologics Collaboration
    • Executive Moves: Daiichi Sankyo Co.
    • Werum, B-EN-G Enter Partnership
    • Janssen, Morphic Ink Deal Worth up to $750M
    • Catalent Appoints Tech Ops SVP
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login